Devin M Parker1, Allen D Everett2, Meagan E Stabler3, Luca Vricella4, Marshall L Jacobs5, Jeffrey P Jacobs5, Chirag R Parikh6, Sara K Pasquali7, Jeremiah R Brown8. 1. Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Lebanon, New Hampshire. Electronic address: devin.m.parker.gr@dartmouth.edu. 2. Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Epidemiology, Geisel School of Medicine, Lebanon, New Hampshire. 4. Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Cardiovascular Surgery, Department of Surgery, Johns Hopkins All Children's Heart Institute, Johns Hopkins All Children's Hospital and Florida Hospital for Children, St Petersburg, Tampa, and Orlando, Florida. 6. Department of Nephrology, Johns Hopkins University, Baltimore, Maryland. 7. Division of Pediatric Cardiology, University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan. 8. Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Lebanon, New Hampshire; Department of Epidemiology, Geisel School of Medicine, Lebanon, New Hampshire; Department of Biomedical Data Science, Geisel School of Medicine, Lebanon, New Hampshire.
Abstract
BACKGROUND: The purpose of this study was to evaluate the association between preoperative biomarker levels and 365-day readmission or mortality after pediatric congenital heart surgery. METHODS: Children aged 18 years or younger undergoing congenital heart surgery (n = 145) at Johns Hopkins Hospital from 2010 to 2014 were enrolled in the prospective cohort. Novel biomarkers suppression of tumorgenicity 2, galectin-3, N-terminal prohormone brain natriuretic peptide, and glial fibrillary acidic protein were measured. The composite study endpoint was unplanned readmission within 365 days after discharge or mortality either in hospital during the surgical admission or within 365 days after discharge. A clinical model based on covariates used in The Society of Thoracic Surgeons Congenital Heart Surgery Database mortality risk model and an augmented model using the clinical model in conjunction with a novel biomarker panel were evaluated. RESULTS: Readmission or mortality within 365 days of surgery occurred among 39 pediatric patients (27%). The clinical model alone resulted in a c-statistic of 0.719 (95% confidence interval, 0.63 to 0.81). The clinical model in conjunction with the log-transformed biomarkers improved the c-statistic to 0.805 (95% confidence interval, 0.73 to 0.88). The addition of biomarkers resulted in a significant improvement to the clinical model alone (P value = 0.035). CONCLUSIONS: Novel biomarkers may add predictive value when assessing the likelihood of 365-day readmission or mortality after pediatric congenital heart surgery. After adjusting for clinical and novel biomarkers, preoperative and postoperative suppression of tumorgenicity 2 remained associated with 365-day readmission or mortality. Currently, The Society of Thoracic Surgeons clinical congenital mortality risk model can be applied to identify children with increased risk of repeat hospitalizations and postdischarge mortality and may inform preventative care interventions that aim to reduce these adverse events.
BACKGROUND: The purpose of this study was to evaluate the association between preoperative biomarker levels and 365-day readmission or mortality after pediatric congenital heart surgery. METHODS:Children aged 18 years or younger undergoing congenital heart surgery (n = 145) at Johns Hopkins Hospital from 2010 to 2014 were enrolled in the prospective cohort. Novel biomarkers suppression of tumorgenicity 2, galectin-3, N-terminal prohormone brain natriuretic peptide, and glial fibrillary acidic protein were measured. The composite study endpoint was unplanned readmission within 365 days after discharge or mortality either in hospital during the surgical admission or within 365 days after discharge. A clinical model based on covariates used in The Society of Thoracic Surgeons Congenital Heart Surgery Database mortality risk model and an augmented model using the clinical model in conjunction with a novel biomarker panel were evaluated. RESULTS: Readmission or mortality within 365 days of surgery occurred among 39 pediatric patients (27%). The clinical model alone resulted in a c-statistic of 0.719 (95% confidence interval, 0.63 to 0.81). The clinical model in conjunction with the log-transformed biomarkers improved the c-statistic to 0.805 (95% confidence interval, 0.73 to 0.88). The addition of biomarkers resulted in a significant improvement to the clinical model alone (P value = 0.035). CONCLUSIONS: Novel biomarkers may add predictive value when assessing the likelihood of 365-day readmission or mortality after pediatric congenital heart surgery. After adjusting for clinical and novel biomarkers, preoperative and postoperative suppression of tumorgenicity 2 remained associated with 365-day readmission or mortality. Currently, The Society of Thoracic Surgeons clinical congenital mortality risk model can be applied to identify children with increased risk of repeat hospitalizations and postdischarge mortality and may inform preventative care interventions that aim to reduce these adverse events.
Authors: Charlotte Kragelund; Bjørn Grønning; Lars Køber; Per Hildebrandt; Rolf Steffensen Journal: N Engl J Med Date: 2005-02-17 Impact factor: 91.245
Authors: D L Williams; A C Gelijns; A J Moskowitz; A D Weinberg; J H Ng; E Crawford; C J Hayes; J M Quaegebeur Journal: J Thorac Cardiovasc Surg Date: 2000-04 Impact factor: 5.209
Authors: Andrew S Mackie; Kimberlee Gauvreau; Jane W Newburger; John E Mayer; Lars C Erickson Journal: Ann Thorac Surg Date: 2004-12 Impact factor: 4.330
Authors: Claire M Lawley; Samantha J Lain; Gemma A Figtree; Gary F Sholler; David S Winlaw; Christine L Roberts Journal: Int J Cardiol Date: 2017-03-27 Impact factor: 4.164
Authors: James L Januzzi; W Frank Peacock; Alan S Maisel; Claudia U Chae; Robert L Jesse; Aaron L Baggish; Michelle O'Donoghue; Rahul Sakhuja; Annabel A Chen; Roland R J van Kimmenade; Kent B Lewandrowski; Donald M Lloyd-Jones; Alan H B Wu Journal: J Am Coll Cardiol Date: 2007-07-30 Impact factor: 24.094
Authors: Alexander R Opotowsky; Fernando Baraona; Justin Owumi; Brittani Loukas; Michael N Singh; Anne Marie Valente; Fred Wu; Susan Cheng; Gruschen Veldtman; Eric B Rimm; Michael J Landzberg Journal: J Am Heart Assoc Date: 2016-01-11 Impact factor: 5.501
Authors: Devin M Parker; Allen D Everett; Meagan E Stabler; Marshall L Jacobs; Jeffrey P Jacobs; Luca Vricella; Heather Thiessen-Philbrook; Chirag R Parikh; Cedric Manlhiot; Jeremiah R Brown Journal: Ann Thorac Surg Date: 2020-04-01 Impact factor: 4.330
Authors: Michael D Green; Devin M Parker; Allen D Everett; Luca Vricella; Marshall L Jacobs; Jeffrey P Jacobs; Jeremiah R Brown Journal: Ann Thorac Surg Date: 2020-08-25 Impact factor: 5.102